Recombinant anti-CD38 fully human monoclonal antibody (Henlius Biotech)

重组抗CD38全人单克隆抗体（复宏汉霖）

Report date: 2026/03/06 20:02:51

Base Information

Drug NameRecombinant anti-CD38 fully human monoclonal antibody (Henlius Biotech)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsAmyloidosisMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fuhong Ruilin Biotechnology Co LtdShanghai Henlius Biologics Co LtdShanghai Henlius Biotech Inc +[4] 
Inactive CompaniesN/A
Active IndicationsAmyloidosisMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A